ITUS CORPORATION (NASDAQ:ITUS) Files An 8-K Regulation FD Disclosure
Item 7.01         Regulation FD Disclosure

On April 4, 2017, ITUS Corporation (the “Company”) issued a press release announcing the closing of its rights offering. The rights offering was made to the Company’s effective registration statement on Form S-3 (Reg. No. 333-206782) on file with the U.S. Securities and Exchange Commission (the “SEC”). The Company raised gross proceeds of approximately $4.7 million before payment of dealer manager fee and other expenses, through the issuance of 1,989,207 shares of common stock in the rights offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information contained in Exhibit 99.1 furnished as an exhibit hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section, and shall not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.           Description

99.1           Press Release dated April 4, 2017

 
 
 
 
 

 About ITUS CORPORATION (NASDAQ:ITUS) 

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body's immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients.
	
ITUS CORPORATION (NASDAQ:ITUS) Recent Trading Information 

ITUS CORPORATION (NASDAQ:ITUS) closed its last trading session down -0.25 at 2.70 with 63,458 shares trading hands.


	
Related